Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iloperidone - Vanda Pharmaceuticals

Drug Profile

Iloperidone - Vanda Pharmaceuticals

Alternative Names: Fanapt; Fanaptum; Fiapta; HP 873; ILO 522; Zomaril

Latest Information Update: 15 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer MegaPharm Ltd; Novartis; PROBIOMED; University of Colorado at Denver; Vanda Pharmaceuticals
  • Class Antipsychotics; Isoxazoles; Piperidines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Schizophrenia
  • Phase II Post-traumatic stress disorders
  • Clinical Phase Unknown Unspecified

Most Recent Events

  • 13 Feb 2019 Vanda Pharmaceuticals plans a clinical trial for Bipolar disorders in 2019
  • 13 Feb 2019 Vanda Pharmaceuticals plans a clinical trial of the long acting injectable formulation of iloperidone for Schizophrenia in 2019
  • 30 Oct 2018 Clinical trials (pharmacokinetic trials) in undisclosed indications (Injection, long acting depot formulation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top